

Elevated Plasma Homocysteine Concentration in Opium-Addicted Individuals

Mohammad Masoomi MD¹, Nahid Azdaki MD², Beydolah Shahouzehi³

Original Article

Abstract

Background: Although the triggering role of both opium use and elevated plasma homocysteine level for progressing atherosclerosis and, therefore, appearing coronary heart disease has been clearly determined, no study are available with respect to the relation between these to risk profiles. In the present study and for the first time, we hypothesized that the opium addiction can be potentially correlated with elevated homocysteine concentration.

Methods: 217 persons (103 opium-addicted and 114 non-addicted) were randomly selected from the Kerman Coronary Artery Disease Risk Study (KERCADRS), Iran, as a population-based, epidemiological prospective study. In all participants, an enzyme immunoassay kit was used to measure homocysteine in serum samples.

Findings: The serum level of homocysteine was significantly higher in the opium-addicted ones compared to non-addicted individuals (11.49 ± 7.45 vs. 8.02 ± 3.87 $\mu\text{mol/l}$) ($P < 0.001$). In this regard, 21.3% of the opium users and only 3.2% of the non-users had homocysteine concentration > 15 $\mu\text{mol/l}$ ($P < 0.001$). On the other hand, individuals addicted to opiates exhibited significantly elevated odds of having homocysteine level higher than 15 [odds ratio (OR) = 8.244, 95% confidence interval (CI) = 3.117-21.806]. Multivariable linear regression model showed that the opium addiction could strongly predict elevated homocysteine level in the study individuals [$\beta = 3.524$, standard error (SE) = 0.852] ($P < 0.001$).

Conclusion: Opium consumption can be strongly accompanied with the elevation of plasma homocysteine concentration, and thus opium addiction can exhibit elevated odds of having hyperhomocysteinemia.

Keywords: Opium addiction, Homocysteine, Cardiovascular disease

Citation: Masoomi M, Azdaki N, Shahouzehi B. **Elevated Plasma Homocysteine Concentration in Opium-Addicted Individuals.** *Addict Health* 2015; 7(3-4)

Received: 19.06.2015

Accepted: 22.08.2015

1- Associate Professor, Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

2- Resident, Atherosclerosis and Coronary Artery Research Center, Brjand University of Medical Sciences, Birjand, Iran

3- PhD Student, Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

Correspondence to: Beydolah Shahouzehi, Email: shahouzehi2007@yahoo.com

Introduction

The majority of prospective studies could show that elevated plasma total homocysteine level was an important risk factor for developing coronary atherosclerosis and pathological changes in cerebrovascular and peripheral vascular systems.¹⁻⁵ Recent investigations have produced some probable mechanisms responsible for the appearance of atherosclerotic lesions following elevation of this biomarker including vascular endothelial defects, increased uptake of modified low density lipoprotein, stimulating proliferation of smooth muscles, and antithrombotic abnormalities.⁶ High levels of homocysteine are believed to promote the formation of oxidation products such as homocysteine and homocysteine disulfides, as well as homocysteine thiolactone, which can damage endothelial cells by excessive sulfation of collagen.⁷⁻⁹

Furthermore, it has been suggested that the defects in intracellular homocysteine metabolism frequently an inadequate intake of folate or vitamins B-6 or B-12 as cofactors or substrates for the enzymes involved in homocysteine metabolism can result in elevated plasma homocysteine concentrations.^{10,11} These metabolic defects are usually occurred following abnormalities in either genetic or nutritional backgrounds.¹²

Besides, the life-threatening events associated with the use of opium or its purified agents have captured the attention of clinical researchers. It has been demonstrated that serum levels of some biochemical risk factors for coronary artery disease (CAD) such as lipoprotein (a) and C-reactive protein were significantly higher in opium-addicted patients and these factors were major determinants of risk factor for premature atherosclerosis.¹³ Furthermore, in some recent clinical studies, role of opium addiction on progressing coronary atherosclerosis and its related poor outcome has been identified.¹⁴⁻¹⁶

Although the triggering role of both opium use and elevated plasma homocysteine level for progressing atherosclerosis and, therefore, appearing coronary heart disease has been clearly determined, no study are available with respect to the relation between these to risk profiles. In the present study and for the first time, we hypothesized that the opium addiction

can be potentially correlated with elevated homocysteine concentration and thus can trigger its serum level elevation.

Methods

The Kerman Coronary Artery Disease Risk Study (KERCADRS), Iran, is a population-based, epidemiological study among 6000 individuals aged 15-75 years and residence in Kerman city addressing the information of six risk factors of coronary artery disease (CAD) including serum lipids, physical activity, alcohol and drugs addiction, mental disorders like stress and depression, hypertension, and diet regimen.¹⁷

These individuals were given the study questionnaires by a general practitioner about their medical history including CAD risk factors: current smoking history (patients regularly smoke a tobacco product/products 1 or more times per day or have smoked in the 30 days prior to admission),¹⁸ hypercholesterolemia (total cholesterol ≥ 5.0 mmol/l, high-density lipoprotein cholesterol ≥ 1.0 mmol/l in men, or ≥ 1.1 mmol/l in women, and triglyceride (TG) ≥ 2.0 mmol/l),¹⁹ family history of CAD (first-degree relatives before the age of 55 in men and 65 years in women),²⁰ hypertension [systolic blood pressure (BP) ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg and/or on antihypertensive treatment],²¹ and diabetes mellitus (DM) [symptoms of diabetes plus at least one of the following: plasma glucose concentration ≥ 11.1 mmol/l, fasting plasma glucose ≥ 7.0 mmol/l, and two-hour postprandial (2-HPP) ≥ 11.1 mmol/l].²²

With regard to recording opium addiction rate, the participants were asked to disclose whether they have ever used any type of drug and still continue. Opium addiction was defined on the basis of the diagnostic and statistical manual of mental disorders-4th edition (DSM-IV) criteria for substance dependence as regularly consumption of inhalation or orally opium more than 3 times per week.²³ Based on this definition, participants were classified into two groups: 1- current opium-addicted cases (n = 850) and 2- non-addicted cases.

In current study and out of the defined KERCADRS study population, 217 men aged 40-70 years were randomly selected and prospectively underwent measurement of homocysteine. Those with malignant disease, severe renal insufficiency,

cirrhosis, active liver disease attributable to viral infection, and/or other acute infectious or inflammatory disorders were all excluded. The study was approved by the research and Ethics Committees of the Kerman University of Medical Sciences and informed consent was obtained from all participants.

BP was measured in sitting position after at least 10 minutes at rest using a Standard Mercury Manometer (Richter, Germany). If abnormal, BP was measured once again at the end of the session (at least 30 minutes after the first measurement) in the same conditions.

For biochemical analysis, blood samples of 5 ml were drawn after 12 hours overnight fasting for measuring lipid profile, fasting blood sugar (FBS), and also homocysteine. Plasma glucose was measured using the glucose oxidase peroxidase method (KIMIA Kit, Code 890410, Iran). The level of serum lipid profile was also determined by standard enzymatic procedures (KIMIA Kit, Code 890201 for serum TG, and Code 890303 for total cholesterol, Iran). An enzyme immunoassay kit (Axis-Shield Diagnostics, UK) was used to measure homocysteine in serum samples. Elevated homocysteine level in men was considered $> 15 \mu\text{mol/l}$.²⁴

The sample size was estimated by the power analysis and sample size (PASS) for Windows software (PASS, NCS 2000). Based on the data on Masoomi et al. study,¹ the groups size of 90 achieved 90% power to detect at least 3.0% increase in homocysteine level in the opium-addicted group, with a significance level (alpha) of 0.05. Allowing for a 10% dropout rate, the study required at least 100 participants per arm 1.

Results were presented as mean \pm standard

deviation (SD) for quantitative variables and were summarized by absolute frequencies and percentages for categorical variables. Categorical variables were compared using chi-square test or Fisher's exact test when more than 20% of cells with expected count of < 5 were observed. Quantitative variables were also compared using t-test. Correlation between homocysteine level and other parameters were examined using the Pearson's correlation coefficient test. Multivariable linear regression analysis was used to determine the role of opium addiction for predicting homocysteine level adjustment for age and risk profiles. Statistical significance was determined as a $P \leq 0.050$. All statistical analysis was performed using SPSS software (version 20, SPSS Inc., Chicago, IL, USA).

Results

Table 1 compares baseline characteristics between the opium-addicted and non-addicted subjects. Regarding measured BP, both systolic and diastolic BPs were significantly lower in the addicted group, while other parameters were similar across the two groups. With respect to the association between serum homocysteine levels, the level of this biomarker was significantly higher in the opium-addicted ones compared to non-addicted individuals (11.49 ± 7.45 vs. $8.02 \pm 3.87 \mu\text{mol/l}$) ($P < 0.001$). In this regard, 21.3% of the opium users and only 3.2% of the non-users had homocysteine concentration $> 15 \mu\text{mol/l}$ ($P < 0.001$). On the other hand, individuals addicted to opiates exhibited significantly elevated odds of having homocysteine level higher than 15 [odds ratio (OR) = 8.244, 95% confidence interval (CI) = 3.117-21.806].

Table 1. Baseline characteristics and laboratory parameters in study population

Characteristics	Opium-addicted group (n = 103)	Non-addicted group (n = 114)	P
Age (year) (mean \pm SD)	43.26 \pm 4.53	42.39 \pm 4.87	0.091
History of hypertension [n (%)]	17 (16.5)	21 (18.4)	0.711
History of diabetes [n (%)]	10 (6.0)	12 (7.2)	0.659
Systolic BP (mmHg) (mean \pm SD)	113.13 \pm 14.68	116.38 \pm 15.41	0.047
Diastolic BP (mmHg) (mean \pm SD)	76.86 \pm 10.00	79.02 \pm 9.75	0.045
FBS (mg/dl) (mean \pm SD)	101.85 \pm 31.16	101.74 \pm 38.06	0.977
Serum total cholesterol (mg/dl) (mean \pm SD)	192.56 \pm 41.84	199.41 \pm 43.64	0.143
Serum TG (mg/dl) (mean \pm SD)	173.93 \pm 129.06	178.79 \pm 122.55	0.724
Serum homocysteine (mg/dl)	11.49 \pm 7.45	8.02 \pm 3.87	< 0.001

SD: Standard deviation; FBS: Fasting blood sugar; BP: Blood pressure; TG: Triglyceride




Figure 1. Correlation between serum homocysteine level and FBS (fasting blood sugar)
FBS: Fasting blood sugar

Table 2. Multivariable linear analysis for determining role of opium addiction for predicting elevation of plasma homocysteine level

Item	Beta	SE	P
Opium addiction	-3.524	0.852	< 0.001
Age	-0.105	0.092	0.253
History of hypertension	-0.100	1.171	0.932
History of diabetes	1.274	1.662	0.445
Systolic BP (mmHg)	0.014	0.043	0.736
Diastolic BP (mmHg)	-0.036	0.062	0.565
FBS (mg/dl)	0.032	0.014	0.024
Serum total cholesterol (mg/dl)	0.015	0.010	0.145

FBS: Fasting blood sugar; BP: blood pressure; SE: Standard error

Among different laboratory parameters including FBS, systolic and diastolic BPs, and lipid profiles, homocysteine level had a significant linear correlation only with FBS ($r = 0.173$, $P = 0.002$) (Figure 1). Multivariable linear regression model (Table 2) showed that opium addiction could strongly predict elevated homocysteine level in the study individuals [$\beta = 3.524$, standard error (SE) = 0.852] ($P < 0.001$).

Discussion

In some recent studies particularly on diabetics, it

has been clearly determined an association between the elevation of plasma homocysteine levels and higher prevalence of some diabetes complications such as peripheral arteriopathy and nephropathy. Furthermore, it has been suggested that the elevated homocysteine can be associated with high levels of fibrinogen, lipoprotein (a), microalbuminuria, and BP levels.²⁵ In some others, the association between serum homocysteine level and traditional CAD risk factors was only observed for systolic hypertension and there was no significant relationship between homocysteine level and

other coronary risk profiles such as DM, hyperlipidemia, and smoking habit.²⁶ We could show this relationship only for elevated blood sugar that the positive correlation was observed between homocysteine concentration and FBS. Recent studies have demonstrated that under diabetic conditions, the catabolism of homocysteine was enhanced by transcriptional regulation of hepatic cystathionine beta-synthase and these changes were prevented by treatment with insulin.²⁷

In fact, plasma homocysteine levels are elevated in patients with diabetes, particularly in patients with type 2 diabetes as well as in individuals in prediabetes states who exhibit insulin resistance. The levels of homocysteine in such individuals are also influenced by their insulin concentrations, therapy with insulin, and medications such as metformin and glitazones that can either raise or lower homocysteine levels.²⁸ Although we showed a relationship between FBS and homocysteine level, but this relationship was not detected between this marker and presence or absence of the history of DM. It seems that a considerable number of our population with diabetes had an irregular and uncontrolled blood sugar on the time of study. Therefore, it should be assessed this relationship in non-diabetic population or on all patients with diabetes with regular antidiabetic regimens.

Based on our knowledge, this study was the first study that assessed changes in homocysteine level in opium addiction patients. In a study by Kulkarni et al., the effect of heavy alcohol consumption on serum malondialdehyde, homocysteine status, and glutathione-S-transferase activities in alcoholics consuming illicit liquor from the lower socioeconomic background.²⁹ They showed an increase in serum homocysteine level in heavy alcohol drinkers and indicated that increasing homocysteine activities might enhance the susceptibility to vascular diseases in heavy illicit drinkers with poor nutritional status; however, it seems that the

pathophysiological effects of opium use on concentration and activation of homocysteine might be different of alcohol use.²⁹ It has been demonstrated that opiate addicts present lower levels in folic acid than the control group, but no significant differences were observed for vitamin B-12.³⁰ This can explain the changes in level and homocysteine metabolism in opium users. Moreover, deleterious effects of opium consumption on homocysteine metabolism might be explained by its effects on nutritional status. Opium use can cause poor appetite and apathy regarding diet and nutrition.

Opiate addicts and especially those with heavier consumption, develop anorexia which is determined by the poor consumption of food and drink leading to malnutrition.³¹ Morabia et al. have deduced that opiate addicts replace foods that are rich in fat and animal proteins with those that are rich in carbohydrates, especially sucrose and alcohol.³² It can result in an abnormality in homocysteine metabolism or its related enzymatic synthesis processes. Although the current evidence on this subject should be provided more and our obtained relationship between plasma homocysteine level and opium addiction especially with considering amount and root of consumption should be studied more.

Conclusion

The study indicated that opium consumption can be accompanied with the elevation of plasma homocysteine concentration.

Conflict of Interests

The Authors have no conflict of interest.

Acknowledgements

This study was part of the KERCADRS study approved by the Physiology Research Center of Kerman University of Medical Sciences. The authors would like to thank all subjects who participated in this study.

References

1. Masoomi M, Bahrapour A, Mireskandri M, Nematollahi A. Plasma homocysteine concentrations in young patients with acute myocardial infarction. *ARYA Atheroscler* 2007; 2(4): 193-6.
2. Malinow MR. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. *Clin Chem* 1995; 41(1): 173-6.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma

- homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA* 1995; 274(13): 1049-57.
4. Kang SS, Wong PW, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. *J Clin Invest* 1986; 77(5): 1482-6.
 5. Genest JJ, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. *J Am Coll Cardiol* 1990; 16(5): 1114-9.
 6. Ubbink JB, Vermaak WJ, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. *Klin Wochenschr* 1991; 69(12): 527-34.
 7. von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. *Arterioscler Thromb* 1994; 14(3): 460-4.
 8. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB, Editor. *Atherosclerotic cardiovascular disease, hemostasis, and endothelial function*. London, UK: Taylor & Francis; 1992. p. 183-236.
 9. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. *Thromb Res* 1993; 71(5): 337-59.
 10. Graham IM, O'Callaghan P. The role of folic acid in the prevention of cardiovascular disease. *Curr Opin Lipidol* 2000; 11(6): 577-87.
 11. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA* 1993; 270(22): 2693-8.
 12. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. *J Nutr* 1994; 124(10): 1927-33.
 13. Das B, Daga MK, Gupta SK. Lipid Pentad Index: A novel bioindex for evaluation of lipid risk factors for atherosclerosis in young adolescents and children of premature coronary artery disease patients in India. *Clin Biochem* 2007; 40(1-2): 18-24.
 14. Masoomi M, Shahesmaeili A, Mirzazadeh A, Tavakoli M, Zia Ali A. Opium addiction and severity of coronary artery disease: a case-control study. *J Res Med Sci* 2010; 15(1): 27-32.
 15. Nemati MH, Astaneh B, Ardekani GS. Effects of opium addiction on bleeding after coronary artery bypass graft surgery: report from Iran. *Gen Thorac Cardiovasc Surg* 2010; 58(9): 456-60.
 16. Masoomi M, Ramezani MA, Karimzadeh H. The relationship of opium addiction with coronary artery disease. *Int J Prev Med* 2010; 1(3): 182-6.
 17. Najafipour H. A survey on cardiovascular risk factors among 15 to 75 years old people living in Kerman and implementing interventions to reduce the level of these risk factors (KERKADR study). [Thesis]. Kerman, Iran: Kerman University of Medical Sciences 2009. [In Persian].
 18. Barrett-Connor E, Giardina EG, Gitt AK, Gudat U, Steinberg HO, Tschoepe D. Women and heart disease: the role of diabetes and hyperglycemia. *Arch Intern Med* 2004; 164(9): 934-42.
 19. Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. *Eur Heart J* 1998; 19(10): 1434-503.
 20. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. *Eur Heart J* 2004; 25(21): 1880-90.
 21. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. *Clin Exp Hypertens* 1999; 21(5-6): 1009-60.
 22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2008; 31(Suppl 1): S55-S60.
 23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association; 2000.
 24. de Luca G, Suryapranata H, Gregorio G, Lange H, Chiariello M. Homocysteine and its effects on in-stent restenosis. *Circulation* 2005; 112(19): e307-e311.
 25. de Luis DA, Fernandez N, Arranz ML, Aller R, Izaola O, Romero E. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. *J Diabetes Complications* 2005; 19(1): 42-6.
 26. Kobori Y, Tanaka N, Matsuoka O, Aikawa M, Shindo N, Kobayashi H, et al. [Influence of serum homocysteine level on coronary atherosclerosis in Japanese]. *J Cardiol* 2004; 43(5): 223-9.
 27. Schalinske KL. Interrelationship between diabetes and homocysteine metabolism: hormonal regulation

- of cystathionine beta-synthase. *Nutr Rev* 2003; 61(4): 136-8.
28. Elias AN, Eng S. Homocysteine concentrations in patients with diabetes mellitus--relationship to microvascular and macrovascular disease. *Diabetes Obes Metab* 2005; 7(2): 117-21.
29. Kulkarni SR, Ravindra KP, Dhume C, Rataboli PV, Rodrigues E, Rodrigues EE. Increased serum homocysteine levels and glutathione-S-transferase activities in alcoholic patients attending de-addiction centre. *Saratov Journal of Medical Scientific Research* 2010; 6: 620-4.
30. Diaz-Flores Estevez JF, Diaz-Flores EF, Hernandez CC, Rodriguez Rodriguez EM, Diaz RC, Serra-Majem L. Application of linear discriminant analysis to the biochemical and haematological differentiation of opiate addicts from healthy subjects: a case-control study. *Eur J Clin Nutr* 2004; 58(3): 449-55.
31. Santolaria-Fernandez FJ, Gomez-Sirvent JL, Gonzalez-Reimers CE, Batista-Lopez JN, Jorge-Hernandez JA, Rodriguez-Moreno F, et al. Nutritional assessment of drug addicts. *Drug Alcohol Depend* 1995; 38(1): 11-8.
32. Morabia A, Fabre J, Chee E, Zeger S, Orsat E, Robert A. Diet and opiate addiction: a quantitative assessment of the diet of non-institutionalized opiate addicts. *Br J Addict* 1989; 84(2): 173-80.

غلظت افزایش یافته هموسیستین در افراد معتاد به تریاک

دکتر محمد معصومی^۱، دکتر ناهید ازدکی^۲، بیداله شاهزهی^۳

مقاله پژوهشی

چکیده

مقدمه: با وجود نقش فزاینده استعمال تریاک و افزایش سطح هموسیستین در جهت پیشرفت آترواسکلروز، بروز بیماری‌های قلبی-عروقی در رابطه با مصرف تریاک به درستی مورد مطالعه قرار نگرفته است. مصرف مواد مخدر یکی از جدی‌ترین معضلات سلامت عمومی بشر در تمام جوامع و تریاک رایج‌ترین نوع ماده مصرفی در ایران می‌باشد. در مطالعه حاضر اعتیاد به تریاک به طور بالقوه در ارتباط با افزایش غلظت هموسیستین بررسی گردید.

روش‌ها: ۲۱۷ نفر از افراد شرکت کننده در طرح قلب سالم مرکز تحقیقات فیزیولوژی کرمان (۱۰۳ نفر معتاد به تریاک و ۱۱۴ نفر غیر معتاد) وارد مطالعه شدند. مقدار هموسیستین در این افراد با استفاده از کیت‌های Elisa اندازه‌گیری شد.

یافته‌ها: مقدار هموسیستین در افراد معتاد به تریاک ($11/49 \pm 7/45$ میکرومول بر لیتر) نسبت به گروه شاهد ($8/02 \pm 3/87$ میکرومول بر لیتر) به طور معنی‌داری بیشتر بود ($P < 0/001$)؛ به طوری که مقدار هموسیستین ۲۱/۳ درصد از افراد معتاد به تریاک و ۳/۲ درصد از افراد گروه شاهد بیش از ۱۵ میکرومول بر لیتر بود ($P < 0/001$). افراد وابسته به تریاک شانس قابل توجهی در افزایش غلظت هموسیستین بیش از ۱۵ میکرومول بر لیتر داشتند [$CI = 3/117-21/806$ (confidence interval) $OR = 8/244$ (odds ratio)]. بر اساس مدل رگرسیون خطی چند متغیره، اعتیاد به تریاک به طور قوی افزایش مقادیر هموسیستین را پیش‌بینی کرد ($P < 0/001$) [$Beta = 3/524$, $SE = 0/852$]. (Standard error)

نتیجه‌گیری: اعتیاد به تریاک به طور قوی با افزایش مقدار هموسیستین ارتباط دارد و از این‌رو مصرف آن می‌تواند عامل خطری برای افزایش هموسیستین باشد و در نتیجه خطر بروز بیماری‌های قلبی-عروقی را افزایش دهد.

واژگان کلیدی: اعتیاد به تریاک، هموسیستین، بیماری‌های قلبی-عروقی

ارجاع: معصومی محمد، ازدکی ناهید، شاهزهی بیداله. غلظت افزایش یافته هموسیستین در افراد معتاد به تریاک. مجله اعتیاد و سلامت ۱۳۹۴؛ ۷ (۳-۴)

تاریخ پذیرش: ۹۴/۵/۳۱

تاریخ دریافت: ۹۴/۳/۲۹

۱- دانشیار، مرکز تحقیقات قلب و عروق، پژوهشکده علوم پایه و بالینی، دانشکده پزشکی، دانشگاه علوم پزشکی کرمان، کرمان، ایران

۲- دستیار، مرکز تحقیقات آترواسکلروز و عروق کرونر، دانشگاه علوم پزشکی بیرجند، بیرجند، ایران

۳- دانشجوی دکتری، مرکز تحقیقات فیزیولوژی، پژوهشکده نوروفارماکولوژی، دانشگاه علوم پزشکی کرمان، کرمان، ایران